Carbidopa Monohydrate

Bezeichnung:Carbidopa Monohydrate

CAS-Nr38821-49-7

Englisch Name:Carbidopa Monohydrate

CBNumberCB7445183

SummenformelC10H16N2O5

Molgewicht244.25

MOL-Datei38821-49-7.mol

Carbidopa Monohydrate physikalisch-chemischer Eigenschaften

storage temp.	Keep in dark place,Inert atmosphere,Room temperature
Löslichkeit	Slightly soluble in water, very slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride. It dissolves in dilute solutions of mineral acids.
Aggregatzustand	Solid
Farbe	White to Off-White
CAS Datenbank	38821-49-7(CAS DataBase Reference)

Sicherheit

WGK Germany	3
RTECS-Nr.	MW5300000
HazardClass	IRRITANT
HS Code	2928002500
Toxizität	mouse,LD50,intraperitoneal,148mg/kg (148mg/kg),SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYEBEHAVIORAL: ATAXIABEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY),Toxicology and Applied Pharmacology. Vol. 29, Pg. 181, 1974.

Gefahreninformationscode (GHS)

Carbidopa Monohydrate Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften
white or yellowish-white powder. almost odorless. combined with levodopa for Parkinson's disease and Parkinson's syndrome.
Originator
Sinemet,Merck Sharp and Dohme,Italy,1974
Verwenden
Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth.
Verwenden
Carbidopa may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by chromatography techniques.
Definition
ChEBI: Carbidopa is the hydrate of 3-(3,4-dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. It has a role as an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor, an antiparkinson drug, a dopaminergic agent and an antidyskinesia agent. It is a member of hydrazines, a hydrate, a monocarboxylic acid and a member of catechols. It contains a carbidopa (anhydrous).
Trademarks
Lodosyn (Bristol-Myers Squibb).
Therapeutic Function
Muscle relaxant, Antiparkinsonian
Allgemeine Beschreibung
Carbidopa, (S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid, is a whitecrystalline powder, slightly soluble in water (pK_a＝7.8).Carbidopa is absorbed slower than levodopa and is 36%plasma protein bound.Carbidopa is metabolized to twomain metabolites (α-methyl-3-methoxy-4-hydroxyphenylpropionicacid and α-methyl-3,4-dihydroxyphenylpropionicacid). These two metabolites are primarily eliminated in theurine unchanged or as glucuronide conjugates. Unchangedcarbidopa accounts for 30% of the total urinary excretion.No drug interactions have been described.

Carbidopa Monohydrate Upstream-Materialien And Downstream Produkte

Carbidopa Monohydrate Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

38821-49-7, Carbidopa Monohydrate Verwandte Suche:

Send Inquriy